| |
Our main strategy in cancer management is providing both conventional and biopharmaceutical agents. Even though novel anticancer agents targeting cancer antigens are replacing for conventional chemotherapeutic agents but still usage of both together shows synergistic effect. Accordingly, we are focusing on all the range of anti-cancer drug classes including:
- Texans
- Alkylating agents
- Anti-metabolites
- Cytotoxic antibiotics
- Anthracyclines
- Monoclonal antibodies
|